Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.

ABSTRACT:

Background

Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed.

Methods

This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).

Results

Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at bas

SUBMITTER: Papalexi E 

PROVIDER: S-EPMC9373318 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature